Loading...
01/11 16:20
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call revealed strong financial performance, with positive EPS growth and a solid cash position. Despite some deceleration in Tier 1 services, the company is optimistic about CertaraIQ's launch and future growth in software sales, driven by AI integration and market demand. The Q&A session highlighted productivity improvements and a favorable software mix, boosting gross margins. While guidance for services is cautious, the overall sentiment is positive, supported by strategic R&D investments and exposure to growing markets. The market cap suggests moderate volatility, aligning with a 'Positive' rating.
Revenue Third quarter revenue of $104.6 million, representing 10% reported year-over-year growth. The growth was attributed to the company's execution against its 2025 goals and investments in R&D and commercial teams.
Adjusted EBITDA Adjusted EBITDA of $35.2 million, representing a margin of 34%. This was an increase from $33.1 million in the third quarter of 2024. The outperformance was due to internal profitability expectations being exceeded.
R&D Investment R&D investment increased by 24% year-over-year, now accounting for 10% of revenue compared to 9% in the prior year period. This increase reflects the company's focus on investing for growth.
Bookings Third quarter bookings of $96.6 million, representing growth of 1% year-over-year. However, bookings in services declined by 9% due to cautious spending behavior among Tier 1 customers.
Software Revenue Software revenue of $43.8 million grew 22% on a reported basis and 6% organically year-over-year. Growth was driven by strong performance from Simcyp and a $5.6 million contribution from Chemaxon.
Services Revenue Services revenue of $60.8 million grew 3% year-over-year on both a reported and organic basis. Growth was led by QSP services, partially offset by softness in regulatory services.
Net Income Net income for the third quarter of 2025 was $1.5 million compared to a net loss of $1.4 million in the third quarter of 2024. The improvement was due to higher adjusted EBITDA and revenue growth.
Adjusted Net Income Adjusted net income for the third quarter of 2025 was $22.2 million compared to $20.3 million for the third quarter of 2024. This reflects the company's improved profitability.
Diluted Earnings Per Share Diluted earnings per share for the third quarter of 2025 was $0.01 compared to a loss of $0.01 per share in the third quarter of 2024. Adjusted diluted earnings per share was $0.14 compared to $0.13 per share in the prior year.
Cash and Cash Equivalents The company finished the quarter with $172.7 million in cash and cash equivalents. This reflects the company's strong liquidity position.
Simcyp PBPK software and QSP services: These areas showed pockets of outperformance, with growing adoption in drug development for dosing, efficacy, and toxicity analysis.
CertaraIQ: A new software for QSP modeling designed to expand biosimulation use across discovery and clinical phases.
Pinnacle 21 Enterprise: A cloud-based upgrade improving regulatory data compliance and submission speed.
Phoenix Cloud: Transitioned customers from on-premise to Certara Cloud deployment, providing significant functionality upgrades.
Biosimulation adoption: Adoption is growing among large pharma and smaller customers, with increased use in drug development stages and technology-enabled services.
Chemaxon acquisition: Acquired in October 2024, it has grown under Certara ownership and is on track to reach corporate average margins by year-end.
Revenue and profitability: Third quarter revenue was $104.6 million, a 10% year-over-year growth. Adjusted EBITDA was $35.2 million, representing a 34% margin.
R&D investment: Increased by 24% year-over-year, now accounting for 10% of revenue.
Bookings: Third quarter bookings were $96.6 million, a 1% growth, with cautious spending behavior observed among Tier 1 customers.
Regulatory services business review: Significant progress in evaluating the business, with a definitive outcome expected by the end of 2025.
Share repurchase program: Approximately $41 million of stock repurchased in 2025 as part of a $100 million program.
Tier 1 Services Bookings: Bookings of $96.6 million came in below expectations, with growth of only 1%. Cautious spending behavior among Tier 1 customers has led to delays in deal timelines, pushing some into late Q4 or 2026.
Regulatory and Biosim Services: Slowdown in deal completion timelines, particularly in regulatory services and biosim services, due to large pharma customers adjusting R&D focus and onshoring initiatives. This slowdown conflicts with historical seasonality trends.
Tier 2 Software Bookings: Performance was below expectations, attributed to timing issues rather than demand.
Regulatory Writing Business: Performance has been inconsistent, though it generates cash for growth investments. Strategic review is ongoing, with a definitive outcome expected by the end of 2025.
Spending Hesitancy Among Large Customers: Hesitancy in spending among large pharma customers has impacted biosimulation services and regulatory bookings, with double-digit declines in regulatory and low single-digit declines in biosim services.
Cost Increases: Higher operating expenses due to increased employee-related costs in sales, marketing, and R&D, as well as higher software amortization and consulting expenses.
Revenue Guidance: Certara has narrowed its revenue guidance for 2025 to a range of $415 million to $420 million, representing 8% to 9% growth compared with 2024.
Adjusted EBITDA Margin Guidance: The company has raised its adjusted EBITDA margin guidance to the high end of its previous range, expecting a margin around 32% for 2025.
Adjusted EPS Guidance: Certara expects adjusted EPS in the range of $0.45 to $0.47 per share for 2025.
Market Trends and Customer Behavior: Certara has observed cautious spending behavior among Tier 1 services customers, with some deal timelines pushed into late 2025 and 2026. Large pharma customers are adjusting R&D focus and onshoring initiatives, impacting decision-making timelines. However, biosimulation adoption is growing across all stages of drug development, particularly in dosing, efficacy, and toxicity analysis.
Product Development and Innovation: Certara has launched several new products, including Pinnacle 21 Enterprise, Phoenix Cloud, and CertaraIQ, aimed at enhancing regulatory compliance, transitioning to cloud-based solutions, and expanding biosimulation use in discovery and clinical phases. Early customer feedback has been positive.
Chemaxon Acquisition: Chemaxon, acquired in October 2024, is on track to reach corporate average margins by the end of 2025 and has contributed $5.6 million to software revenue in Q3 2025.
Regulatory Services Business Review: Certara is in the final stages of a strategic review of its regulatory services business and plans to share a definitive outcome by the end of 2025.
2026 Planning and Market Outlook: Certara is closely monitoring consumer spending patterns and planning for 2026, with a focus on capitalizing on opportunities in biosimulation adoption and drug development.
Share Repurchase Program: Earlier this year, our Board authorized a $100 million share repurchase program. We have repurchased approximately $41 million of stock during 2025.
The earnings call revealed strong financial performance, with positive EPS growth and a solid cash position. Despite some deceleration in Tier 1 services, the company is optimistic about CertaraIQ's launch and future growth in software sales, driven by AI integration and market demand. The Q&A session highlighted productivity improvements and a favorable software mix, boosting gross margins. While guidance for services is cautious, the overall sentiment is positive, supported by strategic R&D investments and exposure to growing markets. The market cap suggests moderate volatility, aligning with a 'Positive' rating.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
